Autoimmune Hemolytic Anemia Clinical Trial
Official title:
Presence of Circulating CD4+CD28 Null T Helper Lymphocytes in Patients With Autoimmune Hemolytic Anemia.
1. Study the presence of circulating CD4+/CD28 null T lymphocytes in AIHA either Idiopathic or Secondary. 2. Role of CD4+/CD28 null T lymphocytes in monitoring response to therapy in AIHA.
Autoimmune hemolytic anemia (AIHA) has always been considered the simplest and most scholastic example of antibody-mediated autoimmune disease.It has been identified as a greatly heterogeneous disease, due to several immunological mechanisms involved beyond antibodies, complement and antibody-dependent cell-mediated cytotoxicity (ADCC). AIHAs may be Idiopathic of unknown cause Secondary associated with several conditions : (lymphoproliferative, autoimmune , infectious diseases, immunodeficiencies, solid tumors, transplants, and drugs).Several subsets of T and B lymphocytes with highly specialized functions have been characterized. Some lymphocytes promote inflammation, while others have anti-inflammatory roles, and an optimal balance between these two opposing sets of lymphocytes is critical for immune homeostasis. A pro-inflammatory subset of CD4+ T helper 1 (Th1) lymphocytes known as cluster of differentiation 4 positive 28 negative T helper lymphocytes (CD4+CD28 null T cells) because they characteristically lack CD28 which is a co-stimulatory receptor critical for the activation and function of T cells.CD4+CD28 null T cells are rare in healthy individuals, but they increase in inflammatory and immune-mediated diseases. Prevalence of CD4+CD28 null T cells is high in chronic inflammatory diseases, autoimmune diseases, immunodeficiency and specific infectious diseases.It remains controversial whether CD4+CD28null T cells are antigen specific and which are the precise antigens that trigger their expansion. It has been suggested that CD4+CD28null T lymphocytes are auto-reactive and that repeated stimulation by auto-antigens drives the expansion of this cell subset.Expansion of the CD4+CD28 null T-cell subset in patients affected by autoimmune disorders has been linked to the severity of disease and an unfavourable prognosis. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT05057481 -
Reappraisal of the Therapies of Refractory Autoimmune Hemolytic Anemia in Systemic Lupus Erythematosus
|
Phase 3 | |
| Recruiting |
NCT05937828 -
OBS'CEREVANCE: French Cohort of Pediatric Autoimmune Cytopenia
|
||
| Recruiting |
NCT05263817 -
A Clinical Study of CD19/BCMA CAR-T Cells in the Treatment of Refractory POEMS Syndrome, Amyloidosis, Autoimmune Hemolytic Anemia, and Vasculitis
|
Early Phase 1 | |
| Completed |
NCT03269292 -
Clinical Characteristics and Treatment Outcomes of Patients With Autoimmune Hemolytic Anemia
|
||
| Recruiting |
NCT05694312 -
Ibrutinib for the Treatment of AIHA in Patients With CLL/SLL or CLL-like MBL
|
Phase 2 | |
| Completed |
NCT03538041 -
A Study of INCB050465 in Participants With Autoimmune Hemolytic Anemia
|
Phase 2 | |
| Recruiting |
NCT03918265 -
Tacrolimus Treatment for Refractory Autoimmune Cytopenia
|
Phase 4 | |
| Completed |
NCT02389231 -
Evaluating the Interest of Interleukine-2 for Patients With Active Warm Hemolytic Anemia Resistant to Conventional Treatment
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT03576742 -
Severe Immune Cytopenia Registry Www.Sic-reg.Org
|
||
| Active, not recruiting |
NCT04657094 -
Acalabrutinib for the Treatment of Relapsed or Refractory Autoimmune Hemolytic Anemia in Patients With Chronic Lymphocytic Leukemia
|
Phase 2 | |
| Recruiting |
NCT02828670 -
Role of T Follicular Helper Cells in Autoimmune Hemolytic Anemia (TFH in AIHA)
|
||
| Recruiting |
NCT02877706 -
French Registry of Adult Patients With Immune Thrombocytopenia and Autoimmune Hemolytic Anemia
|
||
| Recruiting |
NCT05931718 -
Prospective Evaluation of Diagnosis and Treatment of Patients With Autoimmune Cytopenias Including Autoimmune Hemolytic Anemia, Immune Thrombocytopenia, and Chronic Idiopathic/Autoimmune Neutropenia
|
||
| Completed |
NCT02158195 -
Immunopathology of Autoimmune Hemolytic Anemia
|
||
| Completed |
NCT00001630 -
Treatment of Autoimmune Thrombocytopenia (AITP)
|
Phase 1 | |
| Withdrawn |
NCT04039477 -
A Phase 2 Study to Evaluate the Safety and Efficacy of KZR-616 in Patients With AIHA and ITP
|
Phase 2 | |
| Recruiting |
NCT04024202 -
Data Registry of Auto Immune Hemolytic Anemia
|
||
| Completed |
NCT02689986 -
Bendamustine and Rituximab Combination Therapy for Cold Agglutinin Disease
|
Phase 2 | |
| Recruiting |
NCT06212154 -
CAR-T for Autoimmune Hemolytic Anemia Patients Who Have Failed Three or More Lines of Therapy
|
Phase 1 | |
| Completed |
NCT04057703 -
Balance Benefit / Risk of Immunomodulatory Treatments at the Child and Adolescent for Autoimmune Cytopenia.
|